[{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"5d9e3655-cb50-477b-86ac-5e2e42b0f19d","acronym":"BP42675","url":"https://clinicaltrials.gov/study/NCT04826003","created_at":"2021-04-01T16:52:30.647Z","updated_at":"2024-07-02T16:34:37.780Z","phase":"Phase 1/2","brief_title":"Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment","source_id_and_acronym":"NCT04826003 - BP42675","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-06-06"},{"id":"187784db-1075-4994-aa09-cf7fce78d011","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866239","created_at":"2021-01-18T19:04:05.477Z","updated_at":"2024-07-02T16:35:14.437Z","phase":"Phase 1","brief_title":"A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma","source_id_and_acronym":"NCT03866239","lead_sponsor":"Hoffmann-La Roche","biomarkers":" MSI • CEACAM5","pipe":"","alterations":" ","tags":["MSI • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • cibisatamab (RG7802)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 03/13/2024","primary_completion_date":" 03/13/2024","study_txt":" Completion: 03/13/2024","study_completion_date":" 03/13/2024","last_update_posted":"2024-03-15"},{"id":"4fed5445-16f5-4afc-a23e-a964c229154d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02324257","created_at":"2021-01-18T11:01:30.196Z","updated_at":"2024-07-02T16:36:45.906Z","phase":"Phase 1","brief_title":"A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors","source_id_and_acronym":"NCT02324257","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • cibisatamab (RG7802)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 12/30/2014","start_date":" 12/30/2014","primary_txt":" Primary completion: 09/03/2019","primary_completion_date":" 09/03/2019","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-04-17"},{"id":"6081c37d-f019-4e99-ac44-93bef698131a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650713","created_at":"2021-01-18T12:54:17.706Z","updated_at":"2024-07-02T16:36:50.148Z","phase":"Phase 1","brief_title":"A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors","source_id_and_acronym":"NCT02650713","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cibisatamab (RG7802)"],"overall_status":"Completed","enrollment":" Enrollment 228","initiation":"Initiation: 01/07/2016","start_date":" 01/07/2016","primary_txt":" Primary completion: 01/13/2020","primary_completion_date":" 01/13/2020","study_txt":" Completion: 01/13/2020","study_completion_date":" 01/13/2020","last_update_posted":"2020-02-12"}]